(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 9.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Adaptive Biotechnologies's revenue in 2025 is $252,754,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2025 to be $37,273,205,650, with the lowest ADPT revenue forecast at $33,528,328,589, and the highest ADPT revenue forecast at $41,309,673,221. On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $41,860,794,550, with the lowest ADPT revenue forecast at $37,773,947,467, and the highest ADPT revenue forecast at $44,723,266,825.
In 2027, ADPT is forecast to generate $51,268,023,434 in revenue, with the lowest revenue forecast at $46,423,957,019 and the highest revenue forecast at $56,360,934,106.